As of November 6, 2026, Mereo BioPharma Group plc is a publicly traded company (Nasdaq: MREO); its largest reported holder is 683 Capital Management, LLC, with 8.18% on Schedule 13G of January 6, 2026. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13G, January 6, 2026).
Is this your company?
About to sign with, pay or invest in Mereo BioPharma Group plc? See the free Snapshot first.
Free to see. No signup.
Is Mereo BioPharma Group plc a real, registered company?
- Mereo BioPharma Group plc files with the SEC under CIK 1719714 (its SEC filings).
- Its shares are listed under the ticker MREO on Nasdaq (SEC company record).
- Incorporated in X0, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Mereo BioPharma Group plc in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names EcoR1 Capital, LLC (filed 2026-05-15).
Who are Mereo BioPharma Group plc's owners and officers?
Mereo BioPharma Group plc: industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-28).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-28 | Bank Of America Corp /De/ | 3.4% |
| Schedule 13G/A, 2026-08-14 | Ecor1 Capital, LLC | 0.6% |
| Schedule 13G/A, 2026-05-15 | Ecor1 Capital, LLC | 8.4% |
| Schedule 13G, 2026-05-14 | Bank Of America Corp /De/ | 5.1% |
| Schedule 13G/A, 2026-02-17 | Janus Henderson Group PLC | 0% |
| Schedule 13G/A, 2026-02-17 | Northpond Ventures, LP | 0% |
| Schedule 13G/A, 2026-02-13 | Frazier Life Sciences Public Fund, L.P. | 0% |
| Schedule 13G, 2026-01-09 | Ecor1 Capital, LLC | 9.4% |
| Schedule 13G, 2026-01-06 | 683 Capital Management, LLC | 8.18% |
| Schedule 13G/A, 2025-11-14 | Mangrove Partners Im, LLC | 4.9% |
| Schedule 13G/A, 2025-11-14 | Janus Henderson Group PLC | 10.2% |
| Schedule 13G/A, 2025-08-14 | Frazier Life Sciences Public Fund, L.P. | 4.1% |
Questions about who owns Mereo BioPharma Group plc
Who owns Mereo BioPharma Group plc?
On this page, one holder's latest ownership filing reports 5% or more of Mereo BioPharma Group plc: 683 Capital Management, LLC (8.18%, Schedule 13G, filed 2026-01-06).
When did 683 Capital Management, LLC buy into Mereo BioPharma Group plc?
The filings give report dates, not purchase dates. The earliest filing from 683 Capital Management, LLC on this page is the Schedule 13G, filed 2026-01-06, reporting 8.18%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Mereo BioPharma Group plc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Mereo BioPharma Group plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mereo BioPharma Group plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
How much has Mereo BioPharma Group plc raised?
No fundraising or offering filing from Mereo BioPharma Group plc is on file with us.
Keep reading
More on Mereo BioPharma Group plc and the records around it.
Mereo BioPharma Group plc elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Mangrove Partners IM, LLC also filed stake reports on 2 other companies: ChampionsGate Acquisition Corp (Jul 2026), ClearThink 1 Acquisition Corp. (Jul 2026)
- 683 Capital Management, LLC also filed stake reports on 10 other companies: Perceptive Capital Solutions Corp (Aug 2026), Gossamer Bio, Inc. (Jun 2026), FRACTYL HEALTH, INC. (May 2026)
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Alto Neuroscience, Inc. (Jul 2026), Fulcrum Therapeutics, Inc. (Jun 2026), Eloxx Pharmaceuticals, Inc. (Jun 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/mereo-biopharma